| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Clémence Reverdiau, Damien Denima. Advances in the Oral Administration of Somatostatin Receptor Ligands in Acromegaly: A Systematic Review Focusing on Biochemical Response. Pharmaceutics. vol 16. issue 11. 2024-11-27. PMID:39598481. |
advances in the oral administration of somatostatin receptor ligands in acromegaly: a systematic review focusing on biochemical response. |
2024-11-27 |
2024-11-29 |
Not clear |
| Luigi Simone Aversa, Michela Sibilla, Nunzia Prencipe, Valentina Gasco, Ezio Ghigo, Silvia Grottol. Treatment with Long-Acting Somatostatin Analogues in Patients with Acromegaly: When and How. Frontiers of hormone research. vol 55. 2024-11-25. PMID:39586277. |
treatment with long-acting somatostatin analogues in patients with acromegaly: when and how. |
2024-11-25 |
2024-11-28 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Cristian Tebe, Mónica Marazuela, Manel Puig-Doming. Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. Reviews in endocrine & metabolic disorders. 2024-11-11. PMID:39527181. |
pasireotide long-acting release (pas-lar) is a second-generation somatostatin receptor ligand (srl) approved for acromegaly treatment. |
2024-11-11 |
2024-11-17 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Cristian Tebe, Mónica Marazuela, Manel Puig-Doming. Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. Reviews in endocrine & metabolic disorders. 2024-11-11. PMID:39527181. |
this meta-analysis aimed to evaluate the real-world effectiveness and safety of pas-lar in patients with acromegaly resistant to first-generation somatostatin receptor ligands (fgsrl). |
2024-11-11 |
2024-11-17 |
Not clear |
| G N Nurullina, I N Pushkarev, E G Przhiyalkovskay. [Cephalgic syndrome in patients with acromegaly]. Problemy endokrinologii. vol 70. issue 5. 2024-11-07. PMID:39509632. |
the authors evaluated the effect on headache of various methods of acromegaly treatment: transnasal transsphenoidal adenomectomy, radiation therapy and drug therapy with somatostatin analogues, dopamine agonists and growth hormone receptor antagonist. |
2024-11-07 |
2024-11-16 |
Not clear |
| b' Milo\\xc5\\xa1 Gruji\\xc4\\x87, Marija \\xc5\\xbdivkovi\\xc4\\x87 Radojevi\\xc4\\x87, Katarina Jankovi\\xc4\\x87, Neda Milosavljevi\\xc4\\x8. Andrew Victor Schally: Pioneering Neuroendocrinologist and Architect of Luteinizing Hormone-Releasing Hormone Analogs. Cureus. vol 16. issue 9. 2024-10-14. PMID:39398731.' |
beyond lhrh, schally's contributions to the development of somatostatin analogs have also had a significant impact on the management of acromegaly and neuroendocrine tumors. |
2024-10-14 |
2024-10-16 |
Not clear |
| Saikat Fakir, Khadeja-Tul Kubra, Nektarios Barabuti. Octreotide protects against LPS-induced endothelial cell and lung injury. Cellular signalling. 2024-10-07. PMID:39374730. |
octreotide (oct) is an fda-approved synthetic somatostatin analog (ssa) used to treat acromegaly and neuroendocrine tumors. |
2024-10-07 |
2024-10-10 |
mouse |
| Turkan Aliyeva, Juliana Muniz, Gustavo Meira Soares, Sarah Firdausa, Lubna Mirz. Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis. Pituitary. 2024-09-30. PMID:39349787. |
we aimed to perform a systematic review and single-arm meta-analysis to evaluate the efficacy of the multi-receptor somatostatin ligand pasireotide in patients with active or uncontrolled acromegaly. |
2024-09-30 |
2024-10-03 |
Not clear |
| Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Carla Mihaela Tone, Daria Alexandra Hemes, Konstantinos Periferakis, Lamprini Troumpata, Ioana Anca Badarau, Cristian Scheau, Ana Caruntu, Ilinca Savulescu-Fiedler, Constantin Caruntu, Andreea-Elena Schea. Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias. Current issues in molecular biology. vol 46. issue 9. 2024-09-27. PMID:39329930. |
moreover, based on the affinity of somatostatin analogs for the different types of sstrs, the therapeutic range includes conditions such as tumors, acromegaly, post-prandial hypotension, hyperinsulinism, and many more. |
2024-09-27 |
2024-09-29 |
human |
| Maximilian Cosma Gliga, Laura Chinezu, Ionela Maria Pascan. Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin. International journal of molecular sciences. vol 25. issue 16. 2024-08-29. PMID:39201352. |
predicting response to medical treatment in acromegaly via granulation pattern, expression of somatostatin receptors type 2 and 5 and e-cadherin. |
2024-08-29 |
2024-09-01 |
Not clear |
| Maximilian Cosma Gliga, Laura Chinezu, Ionela Maria Pascan. Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin. International journal of molecular sciences. vol 25. issue 16. 2024-08-29. PMID:39201352. |
resistance to first-generation somatostatin receptor ligand (fgsrl) treatment in acromegaly is common, making the identification of biomarkers that predict fgsrl response a desired goal. |
2024-08-29 |
2024-09-01 |
Not clear |
| Bo Zhang, Li Xue, Zhe Bao W. Structure and Function of Somatostatin and its Receptors in Endocrinology. Endocrine reviews. 2024-08-08. PMID:39116368. |
somatostatin analogs, such as octreotide (oct), lanreotide, and pasireotide, which function as somatostatin receptor ligands (srls), are the main drugs used for the treatment of acromegaly. |
2024-08-08 |
2024-08-12 |
Not clear |
| Mirjana Doknic, Marko Stojanovic, Dragana Miljic, Mihajlo Milicevi. Medical treatment of acromegaly - When the tumor size matters: A narrative review. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 78. 2024-08-08. PMID:39116789. |
in this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide lar and lanreotide autogel) and the second generation (pasireotide-lar), as well as pegvisomant (peg) and cabergoline (cab). |
2024-08-08 |
2024-08-12 |
Not clear |
| Montserrat Marques-Pamies, Joan Gil, Miguel Sampedro-Nuñez, Elena Valassi, Betina Biagetti, Olga Giménez-Palop, Marta Hernández, Silvia Martínez, Cristina Carrato, Rocío Villar-Taibo, Marta Araujo-Castro, Concepción Blanco, Inmaculada Simón-Muela, Andreu Simó-Servat, Gemma Xifra, Federico Vázquez, Isabel Pavón, José Antonio Rosado, Rogelio García-Centeno, Roxana Zavala, Felicia Alexandra Hanzu, Mireia Mora, Anna Aulinas, Nuria Vilarrasa, Soledad Librizzi, María Calatayud, Paz de Miguel, Cristina Alvarez-Escola, Antonio Picó, Isabel Salinas, Carmen Fajardo-Montañana, Rosa Cámara, Ignacio Bernabéu, Mireia Jordà, Susan M Webb, Mónica Marazuela, Manel Puig-Doming. Personalized medicine in acromegaly: The ACROFAST study. The Journal of clinical endocrinology and metabolism. 2024-06-29. PMID:38943661. |
medical treatment of acromegaly is currently performed through a trial-error approach using first generation somatostatin receptor ligands (fgsrls) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. |
2024-06-29 |
2024-07-02 |
Not clear |
| Luiz Eduardo Wildemberg, Christhiane Fialho, Mônica R Gadelh. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine. Best practice & research. Clinical endocrinology & metabolism. 2024-06-07. PMID:38845246. |
treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine. |
2024-06-07 |
2024-06-10 |
Not clear |
| Luiz Eduardo Wildemberg, Christhiane Fialho, Mônica R Gadelh. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine. Best practice & research. Clinical endocrinology & metabolism. 2024-06-07. PMID:38845246. |
injectable first-generation somatostatin receptor ligands (fg-srls) are the standard of care of medical treatment for acromegaly. |
2024-06-07 |
2024-06-10 |
Not clear |
| Mônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, Martin Bidlingmaier, Peter J Snyder, Mirtha A Guitelman, Cesar L Boguszewski, Michael Buchfelder, Ilan Shimon, Gerald Raverot, Miklós Tóth, Emese Mezősi, Mirjana Doknic, Xiaolin Fan, David Clemmons, Peter J Trainer, R Scott Struthers, Alan Krasner, Beverly M K Bille. Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. The Journal of clinical endocrinology and metabolism. 2024-06-03. PMID:38828555. |
acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. |
2024-06-03 |
2024-06-05 |
Not clear |
| Mônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, Martin Bidlingmaier, Peter J Snyder, Mirtha A Guitelman, Cesar L Boguszewski, Michael Buchfelder, Ilan Shimon, Gerald Raverot, Miklós Tóth, Emese Mezősi, Mirjana Doknic, Xiaolin Fan, David Clemmons, Peter J Trainer, R Scott Struthers, Alan Krasner, Beverly M K Bille. Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. The Journal of clinical endocrinology and metabolism. 2024-06-03. PMID:38828555. |
paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. |
2024-06-03 |
2024-06-05 |
Not clear |
| S Grottoli, P Maffei, A S Tresoldi, S Granato, L Benedan, P Mariani, A Giustin. Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. Journal of endocrinological investigation. 2024-05-29. PMID:38809458. |
insights from an italian delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. |
2024-05-29 |
2024-06-03 |
Not clear |
| S Grottoli, P Maffei, A S Tresoldi, S Granato, L Benedan, P Mariani, A Giustin. Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. Journal of endocrinological investigation. 2024-05-29. PMID:38809458. |
first-line medical therapy for acromegaly management includes first-generation somatostatin receptor ligands (fgsrls), but resistance limits their use. |
2024-05-29 |
2024-06-03 |
Not clear |